Morgan Stanley Maintains Overweight on PTC Therapeutics, Raises Price Target to $92
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Morgan Stanley analyst Jeffrey Hung maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $90 to $92.
Morgan Stanley analyst Jeffrey Hung maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $90 to $92.